For a second straight year, Cognizant (Teaneck, N.J.) has been named a top provider of digital services for life sciences organizations by Everest Group. The consulting and research firm's new Life Sciences Digital Services PEAK Matrix™ Assessment 2019 reviews 23 global service providers and highlights Cognizant's well-defined vision of helping pharmaceutical and other companies digitally transform to improve productivity, enhance drug safety and ensure regulatory compliance.
Cognizant works with all of the top 30 global pharmaceutical companies, 9 of the top 10 biotech companies and 12 of the top 15 medical device companies helping them implement cloud, artificial intelligence (AI), automation, internet of things (IoT) and other technologies across their value chains. For one life sciences company, Cognizant implemented a robotic process automation (RPA) solution to replace repetitive manual activities related to an increasing volume of individual case safety reports. The Cognizant solution was implemented in just seven months, reduced cycle time by 30% and achieved 99% first-time accuracy, among other benefits.
The new Everest Group report evaluates digital services providers on their proprietary solutions, key investments and technological expertise along with various other market trends and business offerings. Cognizant received top marks for its sustained client engagement, ability to economically optimize client operations and its investments in the sector. Among them is the recent acquisition of Zenith Technologies, which boosted Cognizant's capabilities to design, implement and manage IT systems for connected biopharmaceutical and medical device manufacturers.
"The market size for life sciences digital services is estimated to grow at a rate of 15 to 20 percent through 2021 in North America, with other areas of the world growing at an even faster rate," said Abhishek Singh, Vice President, Everest Group. "Companies like Cognizant, who provide the digital expertise and operational resilience to life sciences clients, will remain at the forefront of this evolving industry, paving the way for companies to meet the evolving needs of their customers and stay ahead of growing competition."
To view an extract of the Everest Group PEAK Matrix Report, visit: https://www.cognizant.com/Resources/everest-group-peak-matix-for-life-sciences-digital-service-providers-2019.pdf
For more about Cognizant Life Sciences Technology Solutions, visit https://www.cognizant.com/life-sciences-technology-solutions
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.